Core Viewpoint - The company, Chongqing Zhixiang Jintai Biopharmaceutical Co., Ltd., has achieved the primary endpoint in the Phase III clinical trial for its drug, Talizhi monoclonal antibody injection (GR1802), for the treatment of adult seasonal allergic rhinitis, and has submitted a new drug application to the National Medical Products Administration (NMPA) which has been accepted [1][2]. Group 1 - Talizhi monoclonal antibody injection (GR1802) is a fully human recombinant anti-IL-4Rα monoclonal antibody that specifically binds to human IL-4Rα on cell surfaces, blocking the binding of IL-4 and IL-13, thereby inhibiting the Th2 inflammatory response mediated by these cytokines [1]. - The drug has also received acceptance for a new drug application for the indication of moderate to severe atopic dermatitis in adults, which was submitted in September 2025 [1]. - Multiple other indications are in various stages of clinical trials, including chronic rhinosinusitis with nasal polyps and chronic spontaneous urticaria in Phase III, asthma in Phase II, and pediatric/adolescent atopic dermatitis in Phase Ib/IIa [1]. Group 2 - As of the announcement date, there are only two other drugs targeting the same mechanism that have been approved for marketing in China [2].

Core Viewpoint - The company reported a significant improvement in financial performance for the fiscal year 2025, with total revenue increasing by 26.18% year-on-year and achieving a net profit attributable to shareholders for the first time [1][2] Financial Performance - Total revenue reached 1.068 billion RMB, marking a year-on-year growth of 26.18% [1] - The net profit attributable to shareholders was 27.8727 million RMB, indicating a turnaround from a loss to profit [1][2] - Basic earnings per share were reported at 0.11 RMB [1] Operational Efficiency - The company implemented cost reduction and efficiency enhancement measures, leading to effective expense management [1][2] - The gross profit margin improved due to optimized production and sales coordination [1] Research and Development - The company continued to advance its R&D projects and international collaborations, receiving government grants and international R&D funding [1] - Non-recurring income related to these grants was recognized during the reporting period [1] Share Capital - The company's share capital was approximately 247 million shares at the end of the reporting period, a decrease of about 410,000 shares due to the cancellation of previously repurchased A-shares [2]

Core Viewpoint - The company, CanSino Biologics (06185.HK), reported a significant improvement in its financial performance for the fiscal year 2025, achieving a total revenue of approximately RMB 1,067.91 million, representing a year-on-year growth of 26.18% and turning a profit for the first time in years [1][2] Financial Performance - The total revenue for the year reached approximately RMB 1,067.91 million, marking a year-on-year increase of 26.18% [1][2] - The net profit attributable to the owners of the parent company was approximately RMB 27.87 million, indicating a turnaround from previous losses [1] - The net loss attributable to the owners of the parent company, after excluding non-recurring gains and losses, was approximately RMB 92.50 million, showing a narrowing of losses compared to the previous year [1][2] Strategic Initiatives - The company continued to focus on innovation and commercialization, with the successful growth of its first quadrivalent meningococcal vaccine, Manhaixin [1] - Cost reduction and efficiency improvement measures were effectively implemented, leading to better expense management and an increase in gross margin [1] - The company benefited from government grants and international research funding, which contributed to non-recurring income during the reporting period [1][2] Operational Efficiency - The company achieved a turnaround in operating profit, total profit, and net profit attributable to the owners of the parent company, all showing positive year-on-year growth [2] - Basic earnings per share and the weighted average return on equity turned positive, reflecting improved operational efficiency [2] - The narrowing of net loss attributable to the owners of the parent company, after excluding non-recurring items, was primarily due to revenue growth and effective resource allocation [2]

Core Viewpoint - Zhonghui Biotech-B (02627) expects to achieve approximately RMB 446 million to RMB 493 million in revenue for the fiscal year 2025, representing an increase of about 71.8% to 89.9% compared to RMB 260 million in revenue for the year ending December 31, 2024. The company anticipates a net loss of approximately RMB 157 million to RMB 197 million for the same period, a reduction of about 23.9% to 39.3% from a net loss of RMB 259 million for the previous year [1] Group 1 - The increase in revenue and reduction in net loss are primarily attributed to the continuous enhancement of the company's quality management system, which ensures a 100% product quality approval rate, thereby lowering sales costs [1] - The implementation of digital precision marketing strategies, including real-time visualization of sales data and targeted marketing policies, has improved the efficiency of marketing expenses while supporting revenue growth [1] - The company has expanded its product delivery to cover 232 disease control centers and 2,563 vaccination clinics, providing more regional options for consumers and directly driving revenue growth [1] Group 2 - Despite a significant increase in listing expenses for 2025, the combined effect of revenue growth and tightened cost control has led to a further narrowing of the net loss for the fiscal year [1]

Core Viewpoint - The company reported a significant improvement in financial performance for the fiscal year 2025, with total revenue reaching 1.068 billion RMB, marking a year-on-year growth of 26.18% and a return to profitability with a net profit of 27.87 million RMB [1][2] Financial Performance - Total revenue for the reporting period was 1.068 billion RMB, reflecting a year-on-year increase of 26.18% [1][2] - The net profit attributable to the parent company was 27.87 million RMB, indicating a turnaround from a loss to profit [1][2] - Basic earnings per share were reported at 0.11 RMB, with the weighted average return on equity turning positive [2] Operational Efficiency - The company implemented cost reduction and efficiency enhancement measures, leading to significant savings in various expenses [2] - Resource allocation was optimized, contributing to improved operational efficiency during the reporting period [2] Product Development and Support - The company continued to focus on innovation and commercialization, with the growth of its first quadrivalent meningococcal vaccine, Manhaixin® [1] - The company received government grants and international research funding, which contributed to non-recurring income during the reporting period [1]

Core Viewpoint - The company Baotai (688177.SH) reported a revenue of 934 million yuan for the fiscal year 2025, marking a year-on-year growth of 25.64%, despite a net loss attributable to shareholders of 336 million yuan [1] Financial Performance - The company achieved a total revenue of 934 million yuan, reflecting a 25.64% increase compared to the previous year [1] - The net profit attributable to shareholders was -336 million yuan, with a net profit excluding non-recurring items at -430 million yuan [1] - Basic earnings per share were -0.81 yuan, and the weighted average return on net assets was -62.32% [1] Profitability Improvement - The total profit loss decreased by 174.15 million yuan compared to the same period last year [1] - The net profit attributable to shareholders improved by 173.86 million yuan year-on-year, primarily due to continuous revenue growth [1] Market Expansion - The company actively expanded its market, with sales of Adalimumab injection (Geleli®) and Tocilizumab injection (Shirili®) steadily increasing compared to the previous year [1] - The launch of Ustekinumab injection (STARJEMZA®) in the U.S. contributed to growth in licensing income and sales revenue [1]

Core Viewpoint - Recently, the company announced a supplemental agreement with Hangzhou Xianweida Biotechnology Co., Ltd. regarding the technology transfer of GLP-1 related drugs, which aims to clarify the revenue sharing arrangements for future earnings from the collaboration [1] Revenue Sharing Arrangement - The agreement specifies that the future variable revenue sharing ratio for the targeted products will be: 5% if a recombinant expression process is used; 2.5% if a chemical synthesis process is employed [1]

Group 1 - The Sci-Tech 50 Index opened with a gain of 0.37% and closed at 1485.86 points, with a total trading volume of approximately 83.5 billion yuan, showing a significant increase compared to the previous trading day [1] - The Sci-Tech Comprehensive Index opened with a gain of 0.25% and closed at 1843.20 points, with a total trading volume of about 269.1 billion yuan, also showing a significant increase from the previous trading day [1] - On February 26, 356 stocks in the Sci-Tech Board rose, accounting for approximately 58.94%, with semiconductor stocks leading the gains [1] Group 2 - The average increase of 604 stocks on the Sci-Tech Board was 0.98%, with an average turnover rate of 3.12% and a total trading volume of approximately 269.1 billion yuan [1] - Individual stock performance included Yuean New Materials, Oulai New Materials, and Jepu Te, which all reached a limit-up of about 20%, while Qianyan Biology saw a decline of 8.61%, the largest drop [1] - In terms of trading volume, Hanwujing had the highest at 16.035 billion yuan, while ST Pava had the lowest at 783.94 million yuan [2]

Core Viewpoint - The company reported a significant decline in both revenue and net profit for the fiscal year 2025, primarily influenced by various factors affecting public awareness and willingness to consume vaccines [1] Financial Performance - Total operating revenue for the year was 592 million yuan, representing a year-on-year decrease of 51.85% [1] - Net profit attributable to the parent company was -272 million yuan, a year-on-year decline of 217.22% [1] - Net profit attributable to the parent company, excluding non-recurring gains and losses, was -289 million yuan, reflecting a year-on-year decrease of 225.71% [1] Factors Influencing Performance - The decline in revenue was attributed to several factors, including public awareness of diseases and willingness to receive vaccinations [1] - The company faced returns on confirmed revenue from the herpes zoster live attenuated vaccine due to expiration before administration, contributing to the revenue drop [1] - To enhance public awareness of herpes zoster prevention and fulfill corporate social responsibility, the company actively promoted welfare projects and adjusted prices, leading to a decrease in the unit price of the herpes zoster vaccine, which further impacted revenue [1] - Additionally, a decline in newborn birth rates and increased market competition resulted in reduced sales of the varicella live attenuated vaccine, further contributing to the revenue decline [1]

由@新浪财经、微博联合打造，@微博财经 #达芬奇live# 出品的对话栏目#钱道# 第一期，邀请华熙生 物董事长赵燕，与英才元投资管理有限公司董事长@宋立新 坦诚分享企业抗衰、人心凝聚与科学坚 守。 新浪声明：所有会议实录均为现场速记整理，未经演讲者审阅，新浪网登载此文出于传递更多信息之目 的，并不意味着赞同其观点或证实其描述。 专题：《钱道》：对话上市公司掌门人 在被问到那场"战争"，华熙生物董事长赵燕称有点遗憾的是，私底下支持的人还是不少，但是没有人敢 站出来，公开地大家形成一个行业的共识。她认为科技要给我们带来平权，未来10年重大的疾病都能够 有办法来治愈，人只要为自己的健康负责，都能够活超过120岁。 责任编辑：李昂 新浪声明：所有会议实录均为现场速记整理，未经演讲者审阅，新浪网登载此文出于传递更多信息之目 的，并不意味着赞同其观点或证实其描述。 责任编辑：李昂 由@新浪财经、微博联合打造，@微博财经 #达芬奇live# 出品的对话栏目#钱道# 第一期，邀请华熙生 物董事长赵燕，与英才元投资管理有限公司董事长@宋立新 坦诚分享企业抗衰、人心凝聚与科学坚 守。 专题：《钱道》：对话上市公司掌门人 在被问 ...